The CTMM (Center for Translational Molecular Medicine) is a Netherlands-based public-private partnership. It is dedicated to the development of technologies in molecular medicine that enable early diagnosis and personalized treatment for the main areas of disease causing mortality and diminished quality of life in the western world. Its focus lies on oncology, cardiovascular, neurodegenerative and infectious/auto-immune disease. CTMM operates by inviting, assessing and funding multidisciplinary projects that involve active participation by Netherlands-based academia and industry. All CTMM projects are judged by an independent International Advisory Board and approved by a Supervisory Board based on their significant potential to translate research knowledge into clinical practice. The CTMM is funded by the Dutch government (50%), academia (25%) and industry (25%). Additional funding is provided by supporting foundations on behalf of patients.